A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bendamustine Hydrochloride
/ administration & dosage
Drug Administration Schedule
Drug Resistance, Neoplasm
Granulocyte Colony-Stimulating Factor
/ administration & dosage
Humans
Immunoconjugates
/ administration & dosage
Japan
Lymphoma, Large B-Cell, Diffuse
/ diagnostic imaging
Middle Aged
Positron Emission Tomography Computed Tomography
Progression-Free Survival
Rituximab
/ administration & dosage
bendamustine
diffuse large B-cell lymphoma
polatuzumab vedotin
relapsed/refractory (R/R)
rituximab
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
27
04
2021
received:
14
01
2021
accepted:
28
04
2021
pubmed:
5
5
2021
medline:
9
7
2021
entrez:
4
5
2021
Statut:
ppublish
Résumé
Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m
Identifiants
pubmed: 33942442
doi: 10.1111/cas.14937
pmc: PMC8253277
doi:
Substances chimiques
Antibodies, Monoclonal
0
Immunoconjugates
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
polatuzumab vedotin
KG6VO684Z6
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2845-2854Subventions
Organisme : Chugai Pharmaceutical Co., Ltd
Informations de copyright
© 2021 Chugai Pharmaceutical Co., Ltd. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Cancer Chemother Pharmacol. 2020 May;85(5):831-842
pubmed: 32222808
Bioanalysis. 2013 Jan;5(2):201-26
pubmed: 23330562
Blood. 2007 Jul 15;110(2):616-23
pubmed: 17374736
Blood. 1997 Jun 1;89(11):3909-18
pubmed: 9166827
Jpn J Clin Oncol. 2021 Jan 1;51(1):70-77
pubmed: 33029633
Clin Adv Hematol Oncol. 2016 Oct;14(10):742
pubmed: 27930623
J Clin Oncol. 2013 Jun 10;31(17):2103-9
pubmed: 23650408
Ann Hematol. 2014 Mar;93(3):403-9
pubmed: 23955074
Bioanalysis. 2013 May;5(9):997-1006
pubmed: 23641692
Nat Biotechnol. 2003 Jul;21(7):778-84
pubmed: 12778055
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25
pubmed: 26314773
Cancer Sci. 2021 Jul;112(7):2845-2854
pubmed: 33942442
Blood. 2009 Sep 24;114(13):2721-9
pubmed: 19633198
Expert Opin Investig Drugs. 2011 Jan;20(1):75-85
pubmed: 21142808
Cancer Chemother Pharmacol. 2020 Sep;86(3):347-359
pubmed: 32770353
Hematol Oncol Clin North Am. 2016 Dec;30(6):1195-1213
pubmed: 27888875
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Cancer Res. 2009 Mar 15;69(6):2358-64
pubmed: 19258515
Best Pract Res Clin Haematol. 2018 Sep;31(3):209-216
pubmed: 30213390
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
J Clin Oncol. 2017 Nov 1;35(31):3529-3537
pubmed: 28796588